News • Improved patient response
Existing heart drugs may help with PD(L)1 immunotherapy
Researchers have found that a class of commonly-used heart drugs may also improve patients’ responses to anti-cancer immunotherapies called PD(L)1 inhibitors, according to preliminary findings to be presented at the 32th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.